Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06598800 · ClinicalTrials.gov registry record · Phase 1

Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors

A Phase 1 study of Advanced Solid Tumor, sponsored by BeiGene.

Recruiting
Registry status
Phase 1
Development phase
87
Enrollment target
20
Study locations

NCT06598800 is a Phase 1 study of Advanced Solid Tumor that is actively recruiting participants, run by BeiGene. The registered enrollment target is 87 participants, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (55% lower). The trial reports 20 study locations across 18 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06598800, a Phase 1 study of Advanced Solid Tumor, is actively recruiting participants, sponsored by BeiGene.

RECRUITING
Registry status
Phase 1
Development phase
87 participants
Enrollment target
20
Study locations

Study Summary

This is a first-in-human (FIH), Phase 1a/1b, open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-T187 alone and in combination with other therapeutic agents in participants with advanced solid tumors.

Conditions Studied

Advanced Solid Tumor

Interventions

  • DRUG Drug: BG-T187
  • DRUG Other Therapeutic Agents

Study Locations (20)

New South Wales

  • Blacktown Cancer and Haematology Centre - Blacktown
  • Macquarie University - North Ryde

Hubei

  • Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology - Wuhan
  • Hubei Cancer Hospital - Wuhan

New Jersey

  • Hackensack University Medical Center - Hackensack

Texas

  • The University of Texas Md Anderson Cancer Center - Houston

Virginia

  • Next Virginia - Fairfax

Wisconsin

  • Washington University, St Louis, Division of Oncology - Madison

Victoria

  • Cabrini Hospital Malvern - Malvern East

Western Australia

  • Linear Clinical Research - Nedlands

Trial Details

FieldValue
Enrollment Target 87 participants
Start Date 2024-10-18
Est. Completion 2028-09-30
Phase Phase 1

Sponsor

BeiGene

65 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06598800

The ClinicalTrials.gov registry entry for NCT06598800 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (55% lower). The listed sponsor is BeiGene, which has 65 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which Drug: BG-T187 is the first listed.

NCT06598800 reports 20 study locations spanning 18 distinct geographic areas - top geographies include New South Wales, Hubei, New Jersey.

Frequently Asked Questions

What is clinical trial NCT06598800 about?

NCT06598800 is a clinical study titled "Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors". This is a first-in-human (FIH), Phase 1a/1b, open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-T187 alone and in combination with other therapeutic agents in partic...

What is the current status of trial NCT06598800?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 87 participants. The study started on 2024-10-18. Estimated completion is 2028-09-30.

What conditions does trial NCT06598800 study?

This clinical trial studies the following conditions: Advanced Solid Tumor.

What interventions are being tested in trial NCT06598800?

The interventions under investigation include: Drug: BG-T187 (DRUG), Other Therapeutic Agents (DRUG).

Who is sponsoring clinical trial NCT06598800?

This trial is sponsored by BeiGene, which has 65 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06598800 being conducted?

This trial has 20 study locations across New Jersey, Texas, Virginia, Wisconsin, New South Wales. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumor

All registered trials for this condition

New Jersey

All trials with a study site in New Jersey

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.